大腸癌(Colorectal Cancer):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Colorectal Cancer - Pipeline Review, H2 2014
◆商品コード:GMDHC5675IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:693
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における大腸癌(Colorectal Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・大腸癌(Colorectal Cancer)の概要
・大腸癌(Colorectal Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・大腸癌(Colorectal Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・大腸癌(Colorectal Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・大腸癌(Colorectal Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Colorectal Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Colorectal Cancer – Pipeline Review, H2 2014’, provides an overview of the Colorectal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Colorectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 8
Colorectal Cancer Overview 9
Therapeutics Development 10
Colorectal Cancer – Therapeutics under Development by Companies 12
Colorectal Cancer – Therapeutics under Investigation by Universities/Institutes 23
Colorectal Cancer – Pipeline Products Glance 26
Colorectal Cancer – Products under Development by Companies 30
Colorectal Cancer – Products under Investigation by Universities/Institutes 43
Colorectal Cancer – Companies Involved in Therapeutics Development 45
Colorectal Cancer – Therapeutics Assessment 169
Drug Profiles 190
Colorectal Cancer – Recent Pipeline Updates 529
Colorectal Cancer – Dormant Projects 643
Colorectal Cancer – Discontinued Products 656
Colorectal Cancer – Product Development Milestones 660
Appendix 667

[List of Tables]
Number of Products under Development for Colorectal Cancer, H2 2014 35
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2014 36
Number of Products under Development by Companies, H2 2014 38
Number of Products under Development by Companies, H2 2014 (Contd..1) 39
Number of Products under Development by Companies, H2 2014 (Contd..2) 40
Number of Products under Development by Companies, H2 2014 (Contd..3) 41
Number of Products under Development by Companies, H2 2014 (Contd..4) 42
Number of Products under Development by Companies, H2 2014 (Contd..5) 43
Number of Products under Development by Companies, H2 2014 (Contd..6) 44
Number of Products under Development by Companies, H2 2014 (Contd..7) 45
Number of Products under Development by Companies, H2 2014 (Contd..8) 46
Number of Products under Development by Companies, H2 2014 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H2 2014 49
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 50
Comparative Analysis by Late Stage Development, H2 2014 51
Comparative Analysis by Clinical Stage Development, H2 2014 52
Comparative Analysis by Early Stage Development, H2 2014 53
Comparative Analysis by Unknown Stage Development, H2 2014 54
Products under Development by Companies, H2 2014 55
Products under Development by Companies, H2 2014 (Contd..1) 56
Products under Development by Companies, H2 2014 (Contd..2) 57
Products under Development by Companies, H2 2014 (Contd..3) 58
Products under Development by Companies, H2 2014 (Contd..4) 59
Products under Development by Companies, H2 2014 (Contd..5) 60
Products under Development by Companies, H2 2014 (Contd..6) 61
Products under Development by Companies, H2 2014 (Contd..7) 62
Products under Development by Companies, H2 2014 (Contd..8) 63
Products under Development by Companies, H2 2014 (Contd..9) 64
Products under Development by Companies, H2 2014 (Contd..10) 65
Products under Development by Companies, H2 2014 (Contd..11) 66
Products under Development by Companies, H2 2014 (Contd..12) 67
Products under Investigation by Universities/Institutes, H2 2014 68
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 69
Colorectal Cancer - Pipeline by 2cureX ApS, H2 2014 70
Colorectal Cancer - Pipeline by 3-V Biosciences, Inc., H2 2014 71
Colorectal Cancer - Pipeline by 4SC AG, H2 2014 72
Colorectal Cancer - Pipeline by Adamed Sp. z o.o., H2 2014 73
Colorectal Cancer - Pipeline by Advaxis, Inc., H2 2014 74
Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 75
Colorectal Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 76
Colorectal Cancer - Pipeline by Agonox, H2 2014 77
Colorectal Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 78
Colorectal Cancer - Pipeline by Amgen Inc., H2 2014 79
Colorectal Cancer - Pipeline by Antibe Therapeutics, Inc., H2 2014 80
Colorectal Cancer - Pipeline by Aphios Corporation, H2 2014 81
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 82
Colorectal Cancer - Pipeline by Astellas Pharma Inc., H2 2014 83
Colorectal Cancer - Pipeline by AstraZeneca PLC, H2 2014 84
Colorectal Cancer - Pipeline by Avipep Pty Ltd, H2 2014 85
Colorectal Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 86
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 87
Colorectal Cancer - Pipeline by Bayer AG, H2 2014 88
Colorectal Cancer - Pipeline by Bionomics Limited, H2 2014 89
Colorectal Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 90
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 91
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2014 92
Colorectal Cancer - Pipeline by Celator Pharmaceuticals, Inc., H2 2014 93
Colorectal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 94
Colorectal Cancer - Pipeline by Cellectis S.A., H2 2014 95
Colorectal Cancer - Pipeline by Celsion Corporation, H2 2014 96
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 97
Colorectal Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 98
Colorectal Cancer - Pipeline by CIMAB S.A., H2 2014 99
Colorectal Cancer - Pipeline by Compugen Ltd., H2 2014 100
Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 101
Colorectal Cancer - Pipeline by CrystalGenomics, Inc., H2 2014 102
Colorectal Cancer - Pipeline by CTI BioPharma Corp., H2 2014 103
Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 104
Colorectal Cancer - Pipeline by Dendreon Corporation, H2 2014 105
Colorectal Cancer - Pipeline by Digna Biotech, S.L., H2 2014 106
Colorectal Cancer - Pipeline by Eddingpharm, H2 2014 107
Colorectal Cancer - Pipeline by Eisai Co., Ltd., H2 2014 108
Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2014 109
Colorectal Cancer - Pipeline by Enzo Biochem, Inc., H2 2014 110
Colorectal Cancer - Pipeline by Erytech Pharma SA, H2 2014 111
Colorectal Cancer - Pipeline by F-star Alpha Ltd., H2 2014 112
Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 113
Colorectal Cancer - Pipeline by Fusion Antibodies Ltd, H2 2014 114
Colorectal Cancer - Pipeline by Genentech, Inc., H2 2014 115
Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H2 2014 116
Colorectal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 117
Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2014 118
Colorectal Cancer - Pipeline by Gradalis Inc., H2 2014 119
Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 120
Colorectal Cancer - Pipeline by Helix BioPharma Corp., H2 2014 121
Colorectal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2014 122
Colorectal Cancer - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 123
Colorectal Cancer - Pipeline by ImmunNovative Developments SL, H2 2014 124
Colorectal Cancer - Pipeline by Immunomedics, Inc., H2 2014 125
Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2014 126
Colorectal Cancer - Pipeline by IMPACT Therapeutics, Inc., H2 2014 127
Colorectal Cancer - Pipeline by Incuron, LLC, H2 2014 128
Colorectal Cancer - Pipeline by Interprotein Corporation, H2 2014 129
Colorectal Cancer - Pipeline by Intezyne, Inc, H2 2014 130
Colorectal Cancer - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 131
Colorectal Cancer - Pipeline by Isofol Medical AB, H2 2014 132
Colorectal Cancer - Pipeline by ISU ABXIS Co.,Ltd., H2 2014 133
Colorectal Cancer - Pipeline by iTeos Therapeutics SA, H2 2014 134
Colorectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 135
Colorectal Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 136
Colorectal Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 137
Colorectal Cancer - Pipeline by Kancera AB, H2 2014 138
Colorectal Cancer - Pipeline by Laboratorio Elea S.A.C.I.F. and A, H2 2014 139
Colorectal Cancer - Pipeline by Lead Discovery Center GmbH, H2 2014 140
Colorectal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 141
Colorectal Cancer - Pipeline by LG Life Sciences, Ltd., H2 2014 142
Colorectal Cancer - Pipeline by Lipopharma Therapeutics SL, H2 2014 143
Colorectal Cancer - Pipeline by LivTech, Inc., H2 2014 144
Colorectal Cancer - Pipeline by MEI Pharma, Inc., H2 2014 145
Colorectal Cancer - Pipeline by Merck & Co., Inc., H2 2014 146
Colorectal Cancer - Pipeline by Merck KGaA, H2 2014 147
Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 148
Colorectal Cancer - Pipeline by MolMed S.p.A., H2 2014 149
Colorectal Cancer - Pipeline by Morphotek, Inc., H2 2014 150
Colorectal Cancer - Pipeline by Multimmune GmbH, H2 2014 151
Colorectal Cancer - Pipeline by Natco Pharma Limited, H2 2014 152
Colorectal Cancer - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2014 153
Colorectal Cancer - Pipeline by Nerviano Medical Sciences, H2 2014 154
Colorectal Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 155
Colorectal Cancer - Pipeline by Novartis AG, H2 2014 156
Colorectal Cancer - Pipeline by NuCana BioMed Limited, H2 2014 157
Colorectal Cancer - Pipeline by Oncobiologics, Inc., H2 2014 158
Colorectal Cancer - Pipeline by Oncology Research International Limited, H2 2014 159
Colorectal Cancer - Pipeline by Oncothyreon Inc., H2 2014 160
Colorectal Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 161
Colorectal Cancer - Pipeline by Oxford BioMedica plc, H2 2014 162
Colorectal Cancer - Pipeline by Panacea Biotec Limited, H2 2014 163
Colorectal Cancer - Pipeline by Pfizer Inc., H2 2014 164
Colorectal Cancer - Pipeline by Philogen S.p.A., H2 2014 165
Colorectal Cancer - Pipeline by PLx Pharma Inc., H2 2014 166
Colorectal Cancer - Pipeline by Precision Biologics, Inc., H2 2014 167
Colorectal Cancer - Pipeline by Quintessence Biosciences, Inc., H2 2014 168
Colorectal Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 169
Colorectal Cancer - Pipeline by Regulon Inc., H2 2014 170
Colorectal Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 171
Colorectal Cancer - Pipeline by Sanofi, H2 2014 172
Colorectal Cancer - Pipeline by Selvita SA, H2 2014 173
Colorectal Cancer - Pipeline by SentoClone International AB, H2 2014 174
Colorectal Cancer - Pipeline by Serina Therapeutics, Inc., H2 2014 175
Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2014 176
Colorectal Cancer - Pipeline by Sigmoid Pharma Limited, H2 2014 177
Colorectal Cancer - Pipeline by SillaJen Co. Ltd., H2 2014 178
Colorectal Cancer - Pipeline by Solvotrin Therapeutics Ltd, H2 2014 179
Colorectal Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 180
Colorectal Cancer - Pipeline by Supratek Pharma Inc., H2 2014 181
Colorectal Cancer - Pipeline by Tactic Pharma, LLC, H2 2014 182
Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 183
Colorectal Cancer - Pipeline by Targovax AS, H2 2014 184
Colorectal Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 185
Colorectal Cancer - Pipeline by TheRyte Ltd., H2 2014 186
Colorectal Cancer - Pipeline by Vaxeal Holding SA, H2 2014 187
Colorectal Cancer - Pipeline by Viralytics Ltd., H2 2014 188
Colorectal Cancer - Pipeline by Wellstat Biologics Corporation, H2 2014 189
Colorectal Cancer - Pipeline by WntResearch AB, H2 2014 190
Colorectal Cancer - Pipeline by XBiotech USA, Inc., H2 2014 191
Colorectal Cancer - Pipeline by Zymeworks Inc., H2 2014 192
Colorectal Cancer - Pipeline by Zyngenia, Inc., H2 2014 193
Assessment by Monotherapy Products, H2 2014 194
Assessment by Combination Products, H2 2014 195
Number of Products by Stage and Target, H2 2014 197
Number of Products by Stage and Mechanism of Action, H2 2014 205
Number of Products by Stage and Route of Administration, H2 2014 212
Number of Products by Stage and Molecule Type, H2 2014 214
Colorectal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 554
Colorectal Cancer - Dormant Projects, H2 2014 668
Colorectal Cancer - Dormant Projects (Contd..1), H2 2014 669
Colorectal Cancer - Dormant Projects (Contd..2), H2 2014 670
Colorectal Cancer - Dormant Projects (Contd..3), H2 2014 671
Colorectal Cancer - Dormant Projects (Contd..4), H2 2014 672
Colorectal Cancer - Dormant Projects (Contd..5), H2 2014 673
Colorectal Cancer - Dormant Projects (Contd..6), H2 2014 674
Colorectal Cancer - Dormant Projects (Contd..7), H2 2014 675
Colorectal Cancer - Dormant Projects (Contd..8), H2 2014 676
Colorectal Cancer - Dormant Projects (Contd..9), H2 2014 677
Colorectal Cancer - Dormant Projects (Contd..10), H2 2014 678
Colorectal Cancer - Dormant Projects (Contd..11), H2 2014 679
Colorectal Cancer - Dormant Projects (Contd..12), H2 2014 680
Colorectal Cancer - Discontinued Products, H2 2014 681
Colorectal Cancer - Discontinued Products (Contd..1), H2 2014 682
Colorectal Cancer - Discontinued Products (Contd..2), H2 2014 683
Colorectal Cancer - Discontinued Products (Contd..3), H2 2014 684

[List of Figures]
Number of Products under Development for Colorectal Cancer, H2 2014 35
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2014 36
Number of Products under Development by Companies, H2 2014 37
Number of Products under Investigation by Universities/Institutes, H2 2014 48
Comparative Analysis by Late Stage Development, H2 2014 51
Comparative Analysis by Clinical Stage Development, H2 2014 52
Comparative Analysis by Early Stage Products, H2 2014 53
Assessment by Monotherapy Products, H2 2014 194
Assessment by Combination Products, H2 2014 195
Number of Products by Top 10 Targets, H2 2014 196
Number of Products by Stage and Top 10 Targets, H2 2014 196
Number of Products by Top 10 Mechanism of Actions, H2 2014 204
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 204
Number of Products by Top 10 Routes of Administration, H2 2014 211
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 211
Number of Products by Top 10 Molecule Types, H2 2014 213
Number of Products by Stage and Top 10 Molecule Types, H2 2014 213

【掲載企業】

2cureX ApS
3-V Biosciences, Inc.
4SC AG
Adamed Sp. z o.o.
Advaxis, Inc.
Advenchen Laboratories, LLC
Aeterna Zentaris Inc.
Agonox
AlphaMab Co., Ltd
Amgen Inc.
Antibe Therapeutics, Inc.
Aphios Corporation
Arisaph Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Avipep Pty Ltd
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
Bionomics Limited
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CCRP Therapeutics GmbH
Celator Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
Cellectis S.A.
Celsion Corporation
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
CIMAB S.A.
Compugen Ltd.
Critical Outcome Technologies Inc.
CrystalGenomics, Inc.
CTI BioPharma Corp.
Deciphera Pharmaceuticals, LLC
Dendreon Corporation
Digna Biotech, S.L.
Eddingpharm
Eisai Co., Ltd.
Eli Lilly and Company
Enzo Biochem, Inc.
Erytech Pharma SA
F-star Alpha Ltd.
F. Hoffmann-La Roche Ltd.
Fusion Antibodies Ltd
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline plc
Glycotope GmbH
Gradalis Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Helix BioPharma Corp.
Hemispherx Biopharma, Inc.
Igenica Biotherapeutics, Inc.
ImmunNovative Developments SL
Immunomedics, Inc.
Immunovative Therapies, Ltd.
IMPACT Therapeutics, Inc.
Incuron, LLC
Interprotein Corporation
Intezyne, Inc
Isis Pharmaceuticals, Inc.
Isofol Medical AB
ISU ABXIS Co.,Ltd.
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co., Ltd.
Kadmon Corporation, LLC
KAEL-GemVax Co., Ltd.
Kancera AB
Laboratorio Elea S.A.C.I.F. and A
Lead Discovery Center GmbH
Lee's Pharmaceutical Holdings Limited
LG Life Sciences, Ltd.
Lipopharma Therapeutics SL
LivTech, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
MolMed S.p.A.
Morphotek, Inc.
Multimmune GmbH
Natco Pharma Limited
NatureWise Biotech & Medicals Corporation
Nerviano Medical Sciences
Northwest Biotherapeutics, Inc.
Novartis AG
NuCana BioMed Limited
Oncobiologics, Inc.
Oncology Research International Limited
Oncothyreon Inc.
Otsuka Holdings Co., Ltd.
Oxford BioMedica plc
Panacea Biotec Limited
Pfizer Inc.
Philogen S.p.A.
PLx Pharma Inc.
Precision Biologics, Inc.
Quintessence Biosciences, Inc.
Recepta Biopharma S.A.
Regulon Inc.
Rexahn Pharmaceuticals, Inc.
Sanofi
Selvita SA
SentoClone International AB
Serina Therapeutics, Inc.
Shanghai Henlius Biotech Co., Ltd.
Sigmoid Pharma Limited
SillaJen Co. Ltd.
Solvotrin Therapeutics Ltd
Sumitomo Dainippon Pharma Co., Ltd.
Supratek Pharma Inc.
Tactic Pharma, LLC
Taiho Pharmaceutical Co., Ltd.
Targovax AS
Teva Pharmaceutical Industries Limited
TheRyte Ltd.
Vaxeal Holding SA
Viralytics Ltd.
Wellstat Biologics Corporation
WntResearch AB
XBiotech USA, Inc.
Zymeworks Inc.
Zyngenia, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[大腸癌(Colorectal Cancer):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆